company background image
AGTC

Applied Genetic Technologies NasdaqGM:AGTC Stock Report

Last Price

US$0.27

Market Cap

US$18.6m

7D

-9.1%

1Y

-89.6%

Updated

04 Oct, 2022

Data

Company Financials +
AGTC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

AGTC Stock Overview

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases.

Applied Genetic Technologies Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Applied Genetic Technologies
Historical stock prices
Current Share PriceUS$0.27
52 Week HighUS$3.18
52 Week LowUS$0.26
Beta1.26
1 Month Change-31.60%
3 Month Change-66.19%
1 Year Change-89.57%
3 Year Change-91.64%
5 Year Change-92.97%
Change since IPO-98.14%

Recent News & Updates

Jul 26

AGTC receives positive feedback from FDA for manufacturing facility

Applied Genetic Technologies (NASDAQ:AGTC) said the U.S. Food and Drug Administration had provided favorable feedback on the current Good Manufacturing Practice (cGMP) design of AGTC’s manufacturing facility. The facility will support AGTC’s pipeline, including the late-stage development and potential commercialization of its eye diseases therapy like X-Linked Retinitis Pigmentosa (XLRP) and Achromatopsia B3 (ACHMB3) programs. The company said initial operations at the facility are expected to begin in Q4 with GMP capabilities expected to be finalized in Q1 2023. "We expect the facility will also play an important role in support of our promising pipeline of additional clinical and pre-clinical programs," the company said. (AGTC) rose 1.3% premarket.

Jul 12

Applied Genetic Technologies proposes stock offering to fund clinical trials

Applied Genetic Technologies (NASDAQ:AGTC) announced Tuesday it plans to initiate underwritten stock offering that will see the issue of its common shares and accompanying stock purchase warrants. The company intends to use the net proceeds for fund its ongoing Skyline and Vista clinical trials in its X-linked retinitis pigmentosa program and its ongoing Phase 1/2 clinical trials in its Achromatopsia program, its preclinical development programs, investments in its manufacturing facility and for working capital and other general corporate purposes, including scheduled payments under its term loan with Hercules Capital, Inc. AGTC Shares fell 29% after-hours, Tuesday, to trade at $0.60. Earlier: Applied Genetic Technologies raised $9.8M in stock offering

Shareholder Returns

AGTCUS BiotechsUS Market
7D-9.1%5.1%4.4%
1Y-89.6%-20.8%-18.2%

Return vs Industry: AGTC underperformed the US Biotechs industry which returned -22.7% over the past year.

Return vs Market: AGTC underperformed the US Market which returned -20% over the past year.

Price Volatility

Is AGTC's price volatile compared to industry and market?
AGTC volatility
AGTC Average Weekly Movement17.4%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: AGTC is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: AGTC's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1999102Sue Washerhttps://agtc.com

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease.

Applied Genetic Technologies Fundamentals Summary

How do Applied Genetic Technologies's earnings and revenue compare to its market cap?
AGTC fundamental statistics
Market CapUS$18.55m
Earnings (TTM)-US$68.94m
Revenue (TTM)US$325.00k

57.1x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AGTC income statement (TTM)
RevenueUS$325.00k
Cost of RevenueUS$21.76m
Gross Profit-US$21.44m
Other ExpensesUS$47.50m
Earnings-US$68.94m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.02
Gross Margin-6,596.62%
Net Profit Margin-21,213.23%
Debt/Equity Ratio62.5%

How did AGTC perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is AGTC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AGTC?

Other financial metrics that can be useful for relative valuation.

AGTC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does AGTC's PB Ratio compare to its peers?

AGTC PB Ratio vs Peers
The above table shows the PB ratio for AGTC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average2x
IDRA Idera Pharmaceuticals
1.2xn/aUS$24.5m
CYCC Cyclacel Pharmaceuticals
0.6x-14.6%US$17.4m
ENZN Enzon Pharmaceuticals
6xn/aUS$19.9m
CRBP Corbus Pharmaceuticals Holdings
0.4x9.4%US$21.0m
AGTC Applied Genetic Technologies
0.6x3.2%US$18.6m

Price-To-Book vs Peers: AGTC is good value based on its Price-To-Book Ratio (0.6x) compared to the peer average (2x).


Price to Earnings Ratio vs Industry

How does AGTC's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: AGTC is good value based on its Price-To-Book Ratio (0.6x) compared to the US Biotechs industry average (1.7x)


Price to Book Ratio vs Fair Ratio

What is AGTC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AGTC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate AGTC's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of AGTC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AGTC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AGTC's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Applied Genetic Technologies forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


3.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AGTC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AGTC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AGTC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AGTC's revenue (47.6% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: AGTC's revenue (47.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AGTC's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Applied Genetic Technologies performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-43.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AGTC is currently unprofitable.

Growing Profit Margin: AGTC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AGTC is unprofitable, and losses have increased over the past 5 years at a rate of 43.7% per year.

Accelerating Growth: Unable to compare AGTC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AGTC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).


Return on Equity

High ROE: AGTC has a negative Return on Equity (-233.89%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Applied Genetic Technologies's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: AGTC's short term assets ($49.6M) exceed its short term liabilities ($25.2M).

Long Term Liabilities: AGTC's short term assets ($49.6M) exceed its long term liabilities ($12.0M).


Debt to Equity History and Analysis

Debt Level: AGTC has more cash than its total debt.

Reducing Debt: Insufficient data to determine if AGTC's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AGTC has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: AGTC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 22.7% each year


Discover healthy companies

Dividend

What is Applied Genetic Technologies's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Applied Genetic Technologies Dividend Yield vs Market
How does Applied Genetic Technologies dividend yield compare to the market?
SegmentDividend Yield
Company (Applied Genetic Technologies)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.5%
Industry Average (Biotechs)2.7%
Analyst forecast in 3 Years (Applied Genetic Technologies)n/a

Notable Dividend: Unable to evaluate AGTC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AGTC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AGTC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AGTC's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AGTC has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.8yrs

Average management tenure


CEO

Sue Washer (61 yo)

18.92yrs

Tenure

US$1,440,129

Compensation

Ms. Susan B. Washer, also known as Sue, has been the President and Chief Executive Officer of Applied Genetic Technologies Corporation since March 2002. Ms. Washer is an experienced entrepreneur with a str...


CEO Compensation Analysis

Sue Washer's Compensation vs Applied Genetic Technologies Earnings
How has Sue Washer's remuneration changed compared to Applied Genetic Technologies's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$69m

Mar 31 2022n/an/a

-US$63m

Dec 31 2021n/an/a

-US$63m

Sep 30 2021n/an/a

-US$60m

Jun 30 2021US$1mUS$530k

-US$58m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020n/an/a

-US$57m

Sep 30 2020n/an/a

-US$50m

Jun 30 2020US$988kUS$530k

-US$46m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019n/an/a

-US$19m

Sep 30 2019n/an/a

-US$15m

Jun 30 2019US$1mUS$514k

-US$2m

Mar 31 2019n/an/a

US$2m

Dec 31 2018n/an/a

-US$18m

Sep 30 2018n/an/a

-US$19m

Jun 30 2018US$1mUS$502k

-US$21m

Mar 31 2018n/an/a

-US$18m

Dec 31 2017n/an/a

-US$11m

Sep 30 2017n/an/a

-US$4m

Jun 30 2017US$1mUS$487k

US$407k

Mar 31 2017n/an/a

US$6m

Dec 31 2016n/an/a

US$10m

Sep 30 2016n/an/a

US$11m

Jun 30 2016US$2mUS$464k

-US$1m

Compensation vs Market: Sue's total compensation ($USD1.44M) is above average for companies of similar size in the US market ($USD772.75K).

Compensation vs Earnings: Sue's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: AGTC's management team is seasoned and experienced (7.8 years average tenure).


Board Members

Experienced Board: AGTC's board of directors are considered experienced (9.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

NasdaqGM:AGTC Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
01 Jul 22SellUS$6,250Stephen PotterIndividual8,070US$0.77
27 May 22SellUS$3,376Gerald ReynoldsIndividual3,994US$0.85

Ownership Breakdown

What is the ownership structure of AGTC?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders299,6550.4%
Institutions12,791,48218.9%
General Public54,541,05880.6%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 57.8%.


Top Shareholders

Top 25 shareholders own 18.62% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
2.93%
The Vanguard Group, Inc.
1,981,565$543.5k0%no data
2.37%
Portolan Capital Management, LLC
1,605,599$440.4k0%0.05%
2.22%
Millennium Management LLC
1,499,124$411.2k-9.05%no data
2.08%
InterWest Partners LLC
1,404,515$385.3k0%0.09%
1.8%
Strategic Advisers LLC
1,216,061$333.6k0%no data
1.37%
BlackRock, Inc.
923,945$253.4k-17.38%no data
1.2%
Sabby Management, LLC
811,973$222.7k-16.3%0.39%
1%
Geode Capital Management, LLC
679,501$186.4k-0.15%no data
0.56%
Altrinsic Global Advisors, LLC
376,900$103.4k0%no data
0.49%
The Colony Group, LLC
330,287$90.6k39.75%no data
0.45%
Renaissance Technologies LLC
305,740$83.9k157.27%no data
0.39%
T. Rowe Price Group, Inc.
262,055$71.9k0%no data
0.23%
Bridgeway Capital Management, LLC
155,375$42.6k-8.55%no data
0.21%
Susan Washer
143,021$39.2k0%no data
0.19%
State Street Global Advisors, Inc.
127,015$34.8k0%no data
0.18%
Columbia Management Investment Advisers, LLC
124,500$34.2k-2.51%no data
0.15%
Knoll Capital Management
100,000$27.4k0%0.02%
0.14%
Susquehanna Fundamental Investments, LLC
96,020$26.3k0%no data
0.12%
Stifel Asset Management Corp.
80,769$22.2k387.47%no data
0.11%
Wells Fargo & Company, Securities and Brokerage Investments
76,116$20.9k-9.57%no data
0.11%
Northern Trust Global Investments
75,255$20.6k-0.01%no data
0.1%
Hudson River Trading LLC, Asset Management Arm
69,536$19.1k0%no data
0.074%
Shay Capital LLC
50,000$13.7k0%0.01%
0.074%
Magnetar Capital, LLC
50,000$13.7k-39.62%no data
0.07%
Stephen Potter
47,133$12.9k62.79%no data

Company Information

Applied Genetic Technologies Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Applied Genetic Technologies Corporation
  • Ticker: AGTC
  • Exchange: NasdaqGM
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$18.552m
  • Shares outstanding: 67.63m
  • Website: https://agtc.com

Number of Employees


Location

  • Applied Genetic Technologies Corporation
  • 14193 NW 119th Terrace
  • Suite 10
  • Alachua
  • Florida
  • 32615
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AGTCNasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDMar 2014
2GTDB (Deutsche Boerse AG)YesCommon SharesDEEURMar 2014

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/04 00:00
End of Day Share Price2022/10/04 00:00
Earnings2022/06/30
Annual Earnings2022/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.